Alexion Pharmaceuticals is a biopharmaceutical company that has been making waves in the market with its innovative treatments. Its stock symbol is ALXN.
The company's stock has been listed on the NASDAQ stock exchange since 1999.
Alexion Pharmaceuticals has a market capitalization of around $35 billion, making it a significant player in the biotech industry.
The company's stock has experienced fluctuations in its price over the years, but it has generally trended upwards.
Alexion Stock Overview
Alexion Pharmaceuticals is a US-based stock, trading under the symbol ALXN-Q on the NASDAQ.
The NASDAQ is the exchange where you can find Alexion Pharmaceuticals listed, and its symbol is ALXN, often referred to as NASDAQ:ALXN or ALXN-Q.
Alexion Pharmaceuticals is known for its unique dual listing on the NASDAQ, with the symbol ALXN-Q.
Stock Performance
As we take a closer look at Alexion's stock performance, it's clear that the company has seen significant growth over the past year.
The 1-month period saw a low of 178.51, which is a 2.24% increase from its low point on July 19th. This is a relatively small fluctuation compared to other time frames.
The 3-month period has been more impressive, with a low of 164.83, representing a 10.72% increase from its low point on April 29th. This is a notable uptick in the company's stock value.
The 52-week period has been the most dramatic, with a low of 99.91, marking an 82.66% increase from its low point on August 21st, 2020. This is a remarkable turnaround for the company.
Here's a breakdown of Alexion's stock performance over the past few months:
Pharmaceuticals Analyst Opinions
Analysts' opinions on Alexion Pharmaceuticals are varied, with some upgrading the stock and others downgrading it. Analysts' recommendations for Alexion Pharmaceuticals include an upgrade to Outperform from Perform by Oppenheimer.
The average earnings estimate for Alexion Pharmaceuticals is $3.22, with a high estimate of $3.63 and a low estimate of $2.89. The number of estimates is 4.
SVB Leerink has adjusted its price target for Alexion Pharmaceuticals to $173 from $156, while also maintaining its Market Perform rating. This adjustment was made on May 3, 2021.
The growth rate estimate for Alexion Pharmaceuticals is +12.20% year over year. This is based on the prior year's earnings of $2.87.
Here is a summary of the recent analyst recommendations for Alexion Pharmaceuticals:
Frequently Asked Questions
What is the ticker symbol for Alexion?
The ticker symbol for Alexion is ALXN. This is the stock symbol used to trade Alexion shares on the New York Stock Exchange (NYSE).
What happened to Alexion Pharmaceuticals stock?
Alexion Pharmaceuticals stock will be delisted from the Nasdaq Stock Market after the company is acquired. This means the stock will no longer be publicly traded.
How much is Alexion worth?
As of 2020, Alexion's net worth is approximately $24.71 billion. This significant valuation reflects the company's growth and success in the pharmaceutical industry.
Featured Images: pexels.com
